Dornase alfa    (DrugBank: Dornase alfa)

2 diseases
告示番号疾患名(ページ内リンク)臨床試験数
53シェーグレン症候群1
299嚢胞性線維症9

53. シェーグレン症候群 [臨床試験数:234,薬物数:270(DrugBank:85),標的遺伝子数:49,標的パスウェイ数:174
Searched query = "Sjogren syndrome", "Sjögren syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 234 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01357447
(ClinicalTrials.gov)
May 201118/5/2011Pulmozyme for Sjogren's Associated CoughA Double-blind, Placebo-controlled Cross-over Trial of Pulmozyme for Sjogren's Associated CoughSjogren's Syndrome;CoughDrug: Dornase alfa;Drug: SalineUConn HealthNULLWithdrawn18 YearsN/AAll0Phase 1United States

299. 嚢胞性線維症 [臨床試験数:1,592,薬物数:1,539(DrugBank:255),標的遺伝子数:81,標的パスウェイ数:162
Searched query = "Cystic fibrosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
9 / 1,592 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04378153
(ClinicalTrials.gov)
August 25, 20204/5/2020Impact of Discontinuing Chronic Therapies in People With Cystic Fibrosis on Highly Effective CFTR Modulator TherapyA Master Protocol to Test the Impact of Discontinuing Chronic Therapies in People With Cystic Fibrosis on Highly Effective CFTR Modulator Therapy (SIMPLIFY)Cystic FibrosisOther: Discontinuation of hypertonic saline (HS);Other: Continuation of hypertonic saline (HS);Other: Discontinuation of dornase alfa (dnase);Other: Continuation of dornase alfa (dnase)David Nichols, MDCystic Fibrosis Foundation;Dartmouth-Hitchcock Medical Center;University of WashingtonRecruiting12 YearsN/AAll800N/AUnited States
2NCT01712334
(ClinicalTrials.gov)
December 201219/10/2012A Study of the Comparable Efficacy and Safety of Pulmozyme (Dornase Alfa) Delivered by the eRapid Nebulizer System in Patients With Cystic FibrosisA Phase IV Multicenter, Randomized, Open Label, Two-Period, Crossover Study in Patients With Cystic Fibrosis to Evaluate the Comparable Efficacy and Safety of Pulmozyme Delivered by the eRapid Nebulizer SystemCystic FibrosisDrug: dornase alfa [Pulmozyme®]Genentech, Inc.NULLCompleted6 YearsN/AAll99Phase 4United States
3NCT00680316
(ClinicalTrials.gov)
June 200816/5/2008A Study of Pulmozyme® (Dornase Alpha) in 3- to 5-Year-Old Patients With Cystic FibrosisA Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Pulmozyme® in 3- to 5-Year-Old Patients With Cystic FibrosisCystic FibrosisDrug: Dornase alfa;Drug: PlaceboGenentech, Inc.NULLTerminated3 Years5 YearsAll3Phase 4United States
4NCT00534079
(ClinicalTrials.gov)
September 200721/9/2007Nasal Inhalation of Pulmozyme in Patients With Cystic Fibrosis and Chronic RhinosinusitisNasal Inhalation of Dornase Alfa (Pulmozyme) in Patients With Cystic Fibrosis and Chronic Rhinosinusitis - a Double Blind Placebo-controlled Cross-over, Bicenter, Prospective Clinical StudyCystic Fibrosis;RhinosinusitisDrug: Dornase alfa (Pulmozyme);Drug: isotonic salineUniversity of JenaNULLCompleted5 YearsN/ABoth23Phase 3Germany
5NCT00434278
(ClinicalTrials.gov)
March 200711/2/2007A Trial of Pulmozyme Withdrawal on Exercise Tolerance in Cystic Fibrosis Subjects With Severe Lung Disease (TOPIC)A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Pulmozyme Withdrawal on Exercise Tolerance in Cystic Fibrosis Subjects With Severe Lung DiseaseCystic FibrosisDrug: Dornase alfa;Drug: placeboGenentech, Inc.NULLTerminated14 YearsN/AAll27Phase 4United States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT00416182
(ClinicalTrials.gov)
December 200626/12/2006Nasally Delivered Pulmozyme for Sinusitis in Cystic FibrosisThe Use of Nasally Delivered Pulmozyme in the Treatment of Sinusitis in Cystic Fibrosis Patients: A Pilot StudySinusitis;Cystic FibrosisDrug: Pulmozyme (dornase alfa);Drug: PlaceboUniversity of VermontGenentech, Inc.Completed5 YearsN/AAll16Phase 2United States
7NCT00265434
(ClinicalTrials.gov)
December 200513/12/2005Nasal Inhalation of Dornase Alfa (Pulmozyme) in Patients With Cystic Fibrosis and Chronic RhinosinusitisNasal Inhalation of Dornase Alfa (Pulmozyme) in Patients With Cystic Fibrosis and Chronic RhinosinusitisCystic Fibrosis;Chronic RhinosinusitisDrug: PulmozymeUniversity of JenaPD Dr. Joachim Riethmöller, Tübingen;PD Dr. Assen Koitschev, Tübingen;Dr. Gerlind SchneiderCompleted5 YearsN/ABoth5Phase 3Germany
8EUCTR2015-003537-99-Outside-EU/EEA
(EUCTR)
05/07/2016A Study of the Comparable Efficacy and Safety of Pulmozyme (Dornase Alfa) Delivered by the eRapid Nebulizer System in Patients With Cystic FibrosisA PHASE IV MULTICENTER, RANDOMIZED, OPEN LABEL, TWO-PERIOD CROSSOVER STUDY IN PATIENTS WITH CYSTIC FIBROSIS TO EVALUATE THE COMPARABLE EFFICACY AND SAFETY OF PULMOZYME® DELIVERED BY THE ERAPID™ NEBULIZER SYSTEM Cystic Fibrosis
MedDRA version: 19.0;Level: PT;Classification code 10011762;Term: Cystic fibrosis;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Body processes [G] - Genetic Phenomena [G05]
Trade Name: Pulmozyme
Product Name: Pulmozyme
INN or Proposed INN: DORNASE ALFA
F. Hoffmann-La Roche AGNULLNAFemale: yes
Male: yes
80Phase 4United States
9EUCTR2007-001548-36-DE
(EUCTR)
27/07/2009Nasale Inhalation von Pulmozyme bei Patienten mit Mukoviszidose und chronischer Rhinosinusitis mit dem Pari Sinus-Vernebler.- bizentrische, randomisierte, doppel-blinde, placebo-kontrollierte, prospektive klinische Studie -Nasal Inhalation of Dornase alfa (Pulmozyme) in Patients with Cystic Fibrosis and Chronic Rhinosinusitis - pulmozyme-nasal-cfNasale Inhalation von Pulmozyme bei Patienten mit Mukoviszidose und chronischer Rhinosinusitis mit dem Pari Sinus-Vernebler.- bizentrische, randomisierte, doppel-blinde, placebo-kontrollierte, prospektive klinische Studie -Nasal Inhalation of Dornase alfa (Pulmozyme) in Patients with Cystic Fibrosis and Chronic Rhinosinusitis - pulmozyme-nasal-cf Cystic Fibrosis with chronic rhinosinusitisTrade Name: Pulmozyme
Product Name: Pulmozyme
INN or Proposed INN: Dornase alfa
Other descriptive name: recombiant human Desoxyribonuclease ( rhDNase)
University of JenaNULLNot RecruitingFemale: yes
Male: yes
16Phase 3Germany